Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
BeyondSpring presents data on stem cell-based application for plinabulin » 07:27
06/30/20
06/30
07:27
06/30/20
07:27
BYSI

BeyondSpring

$14.71 /

-1.04 (-6.60%)

BeyondSpring announced…

BeyondSpring announced that the Company presented clinical data on BeyondSpring's late-stage asset, Plinabulin, showing potent CD34+ progenitor cell mobilization from bone marrow, which has broad applications for stem cell-based therapies, gene therapy and regenerative medicine. These findings potentially add another indication to Plinabulin, which is known as a "pipeline in a drug." Dr. Ramon Mohanlal, BeyondSpring's CMO and EVP, Research and Development, presented this new data as a poster at this year's ISSCR Annual Meeting. Current approved agents for CD34+ progenitor cell mobilization, such as G-CSFs or Plerixafor, have many limitations. While G-CSFs are highly effective in preventing chemotherapy-induced neutropenia, they come with severe side effects, such as bone pain and thrombocytopenia. To add, multiple doses of short-acting G-CSFs are often needed for the therapy to be effective. Plerixafor is also given by daily injections for four to five days and is a very expensive process and not as effective for CD34+ cells. Additionally, G-CSFs are contra-indicated in Sickle Cell Disorder patients undergoing gene therapy. This results in high rates of adverse events requiring hospitalization, including vaso-occlusive crises, multi-organ failure and even death. Lastly, when side effects such as bone pain, leukocytosis and / or myalgia occur, a G-CSF dose is often reduced to 50 percent, which is less effective for CD34+ cell mobilization. Plinabulin is a novel and potent agent for the prevention of CIN and does not cause bone pain or thrombocytopenia. Plinabulin is given as a single fixed dose - as a 30-minute intravenous infusion - and has a mechanism of action independent from G-CSF of CXCR4. In BeyondSpring's PROTECTIVE-2 Phase 2 study, the team evaluated the effects of CD34+ cell mobilization through combining Plinabulin with the full dose of Pegfilgrastim at 6mg and at lower doses of 3mg and 1.5mg in breast cancer patients receiving taxotere, doxorubicin and cyclophosphamide. The data shows that combining Plinabulin with a low dose of Pegfilgrastim produces statistically significant CD34+ cell counts and increases to values that are comparable to, or numerically higher than, the full dose of Pegfilgrastim alone under severe myelosuppressive conditions. In BeyondSpring's PROTECTIVE-1 Phase 2 study, the Company previously reported that lung cancer patients receiving docetaxel who received a single dose of Plinabulin saw an increase of CD34+ counts to clinically and statistically significant levels under myelosuppressive conditions.

ShowHide Related Items >><<
BYSI BeyondSpring
$14.71 /

-1.04 (-6.60%)

BYSI BeyondSpring
$14.71 /

-1.04 (-6.60%)

06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
BYSI BeyondSpring
$14.71 /

-1.04 (-6.60%)

  • 19
    Jun
  • 25
    Oct
  • 17
    Jul
BYSI BeyondSpring
$14.71 /

-1.04 (-6.60%)

Hot Stocks
BeyondSpring reports preclinical data on plinabulin » 08:13
06/23/20
06/23
08:13
06/23/20
08:13
BYSI

BeyondSpring

$15.00 /

+1.49 (+11.03%)

BeyondSpring announced…

BeyondSpring announced new preclinical research findings that indicate BeyondSpring's lead asset, Plinabulin, enhances immuno-radiotherapy for cancer patients. The results of this preclinical study was highlighted in a poster presentation titled, "Plinabulin, a microtubule destabilizing agent, improves tumor control by enhancing dendritic cell maturation and CD8 T cell infiltration in combination with immunoradiotherapy," at this year's American Association for Cancer Research Virtual Annual Meeting on June 22, 2020. Based on these preclinical findings, including a 100% complete response of the triple I/O combination of Plinabulin, anti-PD-1, and radiation in a PD-1 antibody non-responsive model, the compound is being advanced toward a Phase 1 clinical trial in patients who failed or progressed on PD-1 / PD-L1 antibody treatments. Principal investigator Steven H. Lin, M.D., Ph.D., associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, presented the research data. Additional data highlights include: Preclinical effectiveness: The triple I/O combination of Plinabulin, anti-PD-1 and radiation achieved a 100 percent complete response in a breast cancer model that is not responsive to PD-1 antibody alone. Sequential benefit: Plinabulin's effects on dendritic cell maturation are greater when administered after each dose of fractionated radiotherapy, compared to administration before radiation, or administration only once after the first dose of radiotherapy. Abscopal effect: The Plinabulin triple combination anticancer effects in both irradiated and non-irradiated tumors in the same mice indicate the activation of a systemic anticancer immune response. Notably, CD8 cell levels in the non-irradiated tumors were almost double in the triple combination group compared to anti-PD-1 and radiation alone. Dendritic cell MHCII up-regulation and T-cell tumor infiltration: Plinabulin triple combination significantly increased dendritic cell MHCII expression and T-cell infiltration in the tumor. I/O mechanism: AP-1 and NF-kB molecular pathways are crucial in the Plinabulin-induced maturation of dendritic cells. Peer-reviewed 2019 publications in Chem and Cell Reports demonstrated that Plinabulin is differentiated from all other tubulin-targeted agents through its binding site and kinetics and is among the most potent agents that induce dendritic cell maturation. Dendritic cells are key immune cell types in the activation of the immune system against cancer cells, but currently approved immuno-oncology agents, such as antibodies to PD-1, only take the brakes off of T-cells without activating antigen-presenting cells that stimulate T-cells to attack foreign proteins expressed by cancer cells.

ShowHide Related Items >><<
BYSI BeyondSpring
$15.00 /

+1.49 (+11.03%)

BYSI BeyondSpring
$15.00 /

+1.49 (+11.03%)

06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
BYSI BeyondSpring
$15.00 /

+1.49 (+11.03%)

BYSI BeyondSpring
$15.00 /

+1.49 (+11.03%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:16
06/19/20
06/19
12:16
06/19/20
12:16
AMC

AMC Entertainment

$5.83 /

+0.195 (+3.46%)

, DIS

Disney

$118.58 /

+0.11 (+0.09%)

, T

AT&T

$30.23 /

-0.115 (-0.38%)

, MPC

Marathon Petroleum

$40.23 /

+1.75 (+4.55%)

, ANCUF

Alimentation Couche-Tard

$0.00 /

+ (+0.00%)

, KMX

CarMax

$92.93 /

-5.06 (-5.16%)

, TRUE

TrueCar

$2.97 /

+0.155 (+5.52%)

, NIU

Niu Technologies

$16.97 /

+2.61 (+18.18%)

, DVAX

Dynavax

$6.71 /

+0.58 (+9.46%)

, BYSI

BeyondSpring

$13.69 /

-2.91 (-17.53%)

, HOME

At Home Group

$7.46 /

-0.24 (-3.12%)

Stocks are rising to end…

Open Full Text

ShowHide Related Items >><<
TRUE TrueCar
$2.97 /

+0.155 (+5.52%)

T AT&T
$30.23 /

-0.115 (-0.38%)

NIU Niu Technologies
$16.97 /

+2.61 (+18.18%)

MPC Marathon Petroleum
$40.23 /

+1.75 (+4.55%)

KMX CarMax
$92.93 /

-5.06 (-5.16%)

HOME At Home Group
$7.46 /

-0.24 (-3.12%)

DVAX Dynavax
$6.71 /

+0.58 (+9.46%)

DIS Disney
$118.58 /

+0.11 (+0.09%)

BYSI BeyondSpring
$13.69 /

-2.91 (-17.53%)

AMC AMC Entertainment
$5.83 /

+0.195 (+3.46%)

AMC AMC Entertainment
$5.83 /

+0.195 (+3.46%)

06/17/20 Citi
AMC Entertainment price target raised to $4 from $1 at Citi
06/11/20 Imperial Capital
AMC Entertainment price target raised to $6 from $4 at Imperial Capital
06/10/20 Barrington
Barrington keeps a Market Perform on AMC as reopening begins
06/10/20 B. Riley FBR
AMC Entertainment price target raised to $5 from $4 at B. Riley FBR
DIS Disney
$118.58 /

+0.11 (+0.09%)

06/19/20 Wells Fargo
Disney price target raised to $118 from $107 at Wells Fargo
06/15/20 BofA
BofA boosts Disney target to $146, sees 'compelling' entry point
06/09/20
Fly Intel: Top five analyst downgrades
06/09/20 UBS
Disney price target raised to $126 from $114 at UBS
T AT&T
$30.23 /

-0.115 (-0.38%)

06/15/20 Stephens
Electronic Arts seems like best fit as buyer for WB Interactive, says Stephens
06/15/20 Oppenheimer
EA makes 'most sense' as potential buyer of Warner gaming unit, says Oppenheimer
06/11/20 Wells Fargo
T-Mobile price target raised to $120 from $110 at Wells Fargo
05/21/20 JPMorgan
Dish, AT&T's DirecTV combining could make sense, says JPMorgan
MPC Marathon Petroleum
$40.23 /

+1.75 (+4.55%)

05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
03/24/20 Raymond James
Marathon Petroleum double downgraded to Market Perform at Raymond James
03/24/20 Raymond James
Marathon Petroleum downgraded to Market Perform from Strong Buy at Raymond James
ANCUF Alimentation Couche-Tard
$0.00 /

+ (+0.00%)

06/10/20 TD Securities
Alimentation Couche-Tard price target raised to C$49 from C$43
06/09/20 Stifel
Alimentation Couche-Tard price target raised to C$48 from C$43 at Stifel
05/20/20 BMO Capital
Alimentation Couche-Tard price target raised to C$47 from C$44 at BMO Capital
04/07/20 Stifel
Alimentation Couche-Tard initiated with a Buy at Stifel
KMX CarMax
$92.93 /

-5.06 (-5.16%)

06/16/20 Wedbush
CarMax price target raised to $100 from $90 at Wedbush
06/01/20
Fly Intel: Top five analyst initiations
06/01/20 JPMorgan
JPMorgan starts CarMax with Overweight rating, $105 price target
06/01/20 JPMorgan
CarMax initiated with an Overweight at JPMorgan
TRUE TrueCar
$2.97 /

+0.155 (+5.52%)

06/10/20
Fly Intel: Top five analyst upgrades
06/10/20 B. Riley FBR
B. Riley FBR upgrades TrueCar to Buy on improving auto trends
06/10/20 B. Riley FBR
TrueCar upgraded to Buy from Neutral at B. Riley FBR
03/13/20 Stephens
Stephens still sees 'decent chance' of TrueCar being acquired
NIU Niu Technologies
$16.97 /

+2.61 (+18.18%)

06/19/20 Piper Sandler
Niu Technologies price target raised to $24 from $11 at Piper Sandler
01/28/20 Piper Sandler
'Panicked selling' in China autos may prove short-lived, says Piper Sandler
12/03/19 Piper Sandler
Niu Technologies initiated with an Overweight at Piper Jaffray
DVAX Dynavax
$6.71 /

+0.58 (+9.46%)

06/15/20 Evercore ISI
Dynavax initiated with an Outperform at Evercore ISI
05/19/20 William Blair
William Blair cautious on COVID-driven rally in Dynavax shares
10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
07/10/19 Cantor Fitzgerald
Dynavax upgraded to Overweight from Neutral at Cantor Fitzgerald
BYSI BeyondSpring
$13.69 /

-2.91 (-17.53%)

06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
HOME At Home Group
$7.46 /

-0.24 (-3.12%)

06/19/20 Loop Capital
At Home Group price target raised to $7 from $3 at Loop Capital
03/25/20 Guggenheim
Guggenheim cuts At Home Group to Neutral on 'unprecedented demand uncertainty'
03/25/20 Guggenheim
At Home Group downgraded to Neutral from Buy at Guggenheim
01/21/20 KeyBanc
At Home Group downgraded to Sector Weight from Overweight at KeyBanc
TRUE TrueCar
$2.97 /

+0.155 (+5.52%)

T AT&T
$30.23 /

-0.115 (-0.38%)

MPC Marathon Petroleum
$40.23 /

+1.75 (+4.55%)

KMX CarMax
$92.93 /

-5.06 (-5.16%)

HOME At Home Group
$7.46 /

-0.24 (-3.12%)

DVAX Dynavax
$6.71 /

+0.58 (+9.46%)

DIS Disney
$118.58 /

+0.11 (+0.09%)

BYSI BeyondSpring
$13.69 /

-2.91 (-17.53%)

AMC AMC Entertainment
$5.83 /

+0.195 (+3.46%)

  • 19
    Jun
T AT&T
$30.23 /

-0.115 (-0.38%)

MPC Marathon Petroleum
$40.23 /

+1.75 (+4.55%)

KMX CarMax
$92.93 /

-5.06 (-5.16%)

DIS Disney
$118.58 /

+0.11 (+0.09%)

ANCUF Alimentation Couche-Tard
$0.00 /

+ (+0.00%)

AMC AMC Entertainment
$5.83 /

+0.195 (+3.46%)

TRUE TrueCar
$2.97 /

+0.155 (+5.52%)

T AT&T
$30.23 /

-0.115 (-0.38%)

MPC Marathon Petroleum
$40.23 /

+1.75 (+4.55%)

KMX CarMax
$92.93 /

-5.06 (-5.16%)

HOME At Home Group
$7.46 /

-0.24 (-3.12%)

DVAX Dynavax
$6.71 /

+0.58 (+9.46%)

DIS Disney
$118.58 /

+0.11 (+0.09%)

BYSI BeyondSpring
$13.69 /

-2.91 (-17.53%)

AMC AMC Entertainment
$5.83 /

+0.195 (+3.46%)

T AT&T
$30.23 /

-0.115 (-0.38%)

MPC Marathon Petroleum
$40.23 /

+1.75 (+4.55%)

KMX CarMax
$92.93 /

-5.06 (-5.16%)

HOME At Home Group
$7.46 /

-0.24 (-3.12%)

DVAX Dynavax
$6.71 /

+0.58 (+9.46%)

DIS Disney
$118.58 /

+0.11 (+0.09%)

AMC AMC Entertainment
$5.83 /

+0.195 (+3.46%)

On The Fly
Fly Intel: Pre-market Movers » 08:56
06/19/20
06/19
08:56
06/19/20
08:56
IMRN

Immuron

$7.70 /

-0.33 (-4.11%)

, SHLL

Tortoise Acquisition

$10.25 /

-0.01 (-0.10%)

, MPC

Marathon Petroleum

$38.48 /

+1.33 (+3.58%)

, RYAM

Rayonier Advanced Materials

$2.45 /

-0.01 (-0.41%)

, KMX

CarMax

$97.99 /

+0.995 (+1.03%)

, SWBI

Smith & Wesson Brands

$18.70 /

+0.57 (+3.14%)

, BYSI

BeyondSpring

$16.60 /

-0.85 (-4.87%)

, KRMD

Repro Med Systems

$10.30 /

-0.02 (-0.19%)

, WORK

Slack Technologies

$34.21 /

+1.82 (+5.62%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
WORK Slack Technologies
$34.21 /

+1.82 (+5.62%)

SWBI Smith & Wesson Brands
$18.70 /

+0.57 (+3.14%)

SHLL Tortoise Acquisition
$10.25 /

-0.01 (-0.10%)

RYAM Rayonier Advanced Materials
$2.45 /

-0.01 (-0.41%)

MPC Marathon Petroleum
$38.48 /

+1.33 (+3.58%)

KMX CarMax
$97.99 /

+0.995 (+1.03%)

IMRN Immuron
$7.70 /

-0.33 (-4.11%)

BYSI BeyondSpring
$16.60 /

-0.85 (-4.87%)

IMRN Immuron
$7.70 /

-0.33 (-4.11%)

SHLL Tortoise Acquisition
$10.25 /

-0.01 (-0.10%)

MPC Marathon Petroleum
$38.48 /

+1.33 (+3.58%)

05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
03/24/20 Raymond James
Marathon Petroleum double downgraded to Market Perform at Raymond James
03/24/20 Raymond James
Marathon Petroleum downgraded to Market Perform from Strong Buy at Raymond James
RYAM Rayonier Advanced Materials
$2.45 /

-0.01 (-0.41%)

06/19/20 BofA
Rayonier Advanced Materials double-upgraded to Buy from Underperform at BofA
06/19/20 BofA
Rayonier Advanced Materials upgraded to Buy from Underperform at BofA
06/05/20
Fly Intel: Top five analyst downgrades
06/05/20 RBC Capital
Rayonier Advanced Materials cut to Sector Perform at RBC Capital
KMX CarMax
$97.99 /

+0.995 (+1.03%)

06/16/20 Wedbush
CarMax price target raised to $100 from $90 at Wedbush
06/01/20
Fly Intel: Top five analyst initiations
06/01/20 JPMorgan
JPMorgan starts CarMax with Overweight rating, $105 price target
06/01/20 JPMorgan
CarMax initiated with an Overweight at JPMorgan
SWBI Smith & Wesson Brands
$18.70 /

+0.57 (+3.14%)

06/19/20 Lake Street
Smith & Wesson Brands price target raised to $24 from $19 at Lake Street
06/11/20 Wedbush
Smith & Wesson Brands price target raised to $18 from $8.50 at Wedbush
06/04/20 Craig-Hallum
Smith & Wesson Brands price target raised to $21 from $14 at Craig-Hallum
06/02/20 Lake Street
Smith & Wesson Brands price target raised to $19 from $11.50 at Lake Street
BYSI BeyondSpring
$16.60 /

-0.85 (-4.87%)

06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
KRMD Repro Med Systems
$10.30 /

-0.02 (-0.19%)

WORK Slack Technologies
$34.21 /

+1.82 (+5.62%)

06/19/20 Goldman Sachs
Slack Technologies downgraded to Sell from Neutral at Goldman Sachs
06/05/20 DA Davidson
Slack Technologies price target raised to $32 from $29 at DA Davidson
06/05/20 Monness Crespi
Monness Crespi downgrades Slack to Neutral on 'less compelling' valuation
WORK Slack Technologies
$34.21 /

+1.82 (+5.62%)

SWBI Smith & Wesson Brands
$18.70 /

+0.57 (+3.14%)

RYAM Rayonier Advanced Materials
$2.45 /

-0.01 (-0.41%)

MPC Marathon Petroleum
$38.48 /

+1.33 (+3.58%)

KMX CarMax
$97.99 /

+0.995 (+1.03%)

BYSI BeyondSpring
$16.60 /

-0.85 (-4.87%)

  • 19
    Jun
  • 19
    Jun
WORK Slack Technologies
$34.21 /

+1.82 (+5.62%)

SWBI Smith & Wesson Brands
$18.70 /

+0.57 (+3.14%)

MPC Marathon Petroleum
$38.48 /

+1.33 (+3.58%)

KMX CarMax
$97.99 /

+0.995 (+1.03%)

WORK Slack Technologies
$34.21 /

+1.82 (+5.62%)

SWBI Smith & Wesson Brands
$18.70 /

+0.57 (+3.14%)

MPC Marathon Petroleum
$38.48 /

+1.33 (+3.58%)

KMX CarMax
$97.99 /

+0.995 (+1.03%)

BYSI BeyondSpring
$16.60 /

-0.85 (-4.87%)

WORK Slack Technologies
$34.21 /

+1.82 (+5.62%)

SWBI Smith & Wesson Brands
$18.70 /

+0.57 (+3.14%)

MPC Marathon Petroleum
$38.48 /

+1.33 (+3.58%)

KMX CarMax
$97.99 /

+0.995 (+1.03%)

Syndicate
BeyondSpring 1.93M share Spot Secondary priced at $13.00 » 06:13
06/19/20
06/19
06:13
06/19/20
06:13
BYSI

BeyondSpring

$16.60 /

-0.85 (-4.87%)

The deal range was…

The deal range was $13.00-$13.50. Jefferies and William Blair acted as joint book running managers for the offering.

ShowHide Related Items >><<
BYSI BeyondSpring
$16.60 /

-0.85 (-4.87%)

BYSI BeyondSpring
$16.60 /

-0.85 (-4.87%)

06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
BYSI BeyondSpring
$16.60 /

-0.85 (-4.87%)

  • 19
    Jun
BYSI BeyondSpring
$16.60 /

-0.85 (-4.87%)

Syndicate
BeyondSpring $30M Spot Secondary; price range $13.00-$13.50 » 16:18
06/18/20
06/18
16:18
06/18/20
16:18
BYSI

BeyondSpring

$16.64 /

-0.81 (-4.64%)

Jefferies and William…

Jefferies and William Blair are acting as joint book running managers for the offering.

ShowHide Related Items >><<
BYSI BeyondSpring
$16.64 /

-0.81 (-4.64%)

BYSI BeyondSpring
$16.64 /

-0.81 (-4.64%)

06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
BYSI BeyondSpring
$16.64 /

-0.81 (-4.64%)

BYSI BeyondSpring
$16.64 /

-0.81 (-4.64%)

Syndicate
BeyondSpring files to sell common stock, no amount given » 16:08
06/18/20
06/18
16:08
06/18/20
16:08
BYSI

BeyondSpring

$16.64 /

-0.81 (-4.64%)

Jefferies and William…

Jefferies and William Blair will be acting as joint book-running managers for the offering.

ShowHide Related Items >><<
BYSI BeyondSpring
$16.64 /

-0.81 (-4.64%)

BYSI BeyondSpring
$16.64 /

-0.81 (-4.64%)

06/15/20 William Blair
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair
06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
BYSI BeyondSpring
$16.64 /

-0.81 (-4.64%)

BYSI BeyondSpring
$16.64 /

-0.81 (-4.64%)

Recommendations
BeyondSpring can 'disrupt' $6.5B neutropenia market, says William Blair » 10:48
06/15/20
06/15
10:48
06/15/20
10:48
BYSI

BeyondSpring

$18.31 /

+1.64 (+9.84%)

BeyondSpring announced…

BeyondSpring announced that the Phase III PROTECTIVE-2 trial, which examines the safety and efficacy of plinabulin plus Neulasta versus Neulasta monotherapy, met the primary endpoint of preventing severe neutropenia, which represents the first major advancement in the space after Neupogen's approval in 1991, William Blair analyst Andy Hsieh tells investors in a research note. The announcement "meaningfully reduced the clinical risks of plinabulin and paves the way for a timely submission in both the United States and China," says Hsieh. The analyst believes the statistically significant results reaffirm his view of plinabulin's "potential to disrupt" the large $6.5B chemotherapy-induced neutropenia market in both the United States and China. Hsieh reiterates an Outperform rating on BeyondSpring shares.

ShowHide Related Items >><<
BYSI BeyondSpring
$18.31 /

+1.64 (+9.84%)

BYSI BeyondSpring
$18.31 /

+1.64 (+9.84%)

06/15/20 H.C. Wainwright
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright
06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
02/07/20 Jefferies
Jefferies starts BeyondSpring at Buy, sees potential for new standard of care
BYSI BeyondSpring
$18.31 /

+1.64 (+9.84%)

BYSI BeyondSpring
$18.31 /

+1.64 (+9.84%)

Recommendations
BeyondSpring price target raised to $46 from $30 at H.C. Wainwright » 10:15
06/15/20
06/15
10:15
06/15/20
10:15
BYSI

BeyondSpring

$18.07 /

+1.4 (+8.40%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis raised the firm's price target on BeyondSpring to $46 from $30 and reiterates a Buy rating on the shares after the company announced interim results from the ongoing PROTECTIVE-2 Phase 3 study testing Plinabulin plus Neulasta versus Neulasta alone. It appears that Plinabulin provides patients with "strong protection" against the risks of severe neutropenia during cycle 1 of chemotherapy, Pantginis tells investors in a research note.

ShowHide Related Items >><<
BYSI BeyondSpring
$18.07 /

+1.4 (+8.40%)

BYSI BeyondSpring
$18.07 /

+1.4 (+8.40%)

06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
02/07/20 Jefferies
Jefferies starts BeyondSpring at Buy, sees potential for new standard of care
02/07/20 Jefferies
BeyondSpring initiated with a Buy at Jefferies
BYSI BeyondSpring
$18.07 /

+1.4 (+8.40%)

BYSI BeyondSpring
$18.07 /

+1.4 (+8.40%)

On The Fly
Fly Intel: Pre-market Movers » 08:58
06/15/20
06/15
08:58
06/15/20
08:58
CTLT

Catalent

$69.58 /

+0.87 (+1.27%)

, MRNA

Moderna

$62.00 /

+1.84 (+3.06%)

, SHOP

Shopify

$744.50 /

+19.615 (+2.71%)

, BYSI

BeyondSpring

$16.67 /

+0.11 (+0.66%)

, ISEE

Iveric bio

$3.83 /

+0.08 (+2.13%)

, AZN

AstraZeneca

$51.46 /

-0.11 (-0.21%)

, IRBT

iRobot

$75.33 /

+0.765 (+1.03%)

, JKS

JinkoSolar

$17.84 /

+0.9 (+5.31%)

, BP

BP

$24.74 /

+0.67 (+2.78%)

, HTZ

Hertz

$2.86 /

+0.84 (+41.58%)

, CBIO

Catalyst Biosciences

$7.44 /

+0.31 (+4.35%)

, XOG

Extraction Oil & Gas

$0.64 /

+0.0601 (+10.36%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
XOG Extraction Oil & Gas
$0.64 /

+0.0601 (+10.36%)

SHOP Shopify
$744.50 /

+19.615 (+2.71%)

MRNA Moderna
$62.00 /

+1.84 (+3.06%)

JKS JinkoSolar
$17.84 /

+0.9 (+5.31%)

ISEE Iveric bio
$3.83 /

+0.08 (+2.13%)

IRBT iRobot
$75.33 /

+0.765 (+1.03%)

HTZ Hertz
$2.86 /

+0.84 (+41.58%)

CTLT Catalent
$69.58 /

+0.87 (+1.27%)

CBIO Catalyst Biosciences
$7.44 /

+0.31 (+4.35%)

BYSI BeyondSpring
$16.67 /

+0.11 (+0.66%)

BP BP
$24.74 /

+0.67 (+2.78%)

AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

CTLT Catalent
$69.58 /

+0.87 (+1.27%)

05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/20/20 RBC Capital
Catalent initiated with an Outperform at RBC Capital
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
MRNA Moderna
$62.00 /

+1.84 (+3.06%)

06/12/20 Piper Sandler
Moderna preclinical data supports activity of COVID vaccine, says Piper Sandler
06/11/20 Piper Sandler
Moderna, FDA finalize Phase III trial protocol for mRNA-1273, says Piper Sandler
06/08/20 Barclays
Moderna initiated with an Overweight at Barclays
06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
SHOP Shopify
$744.50 /

+19.615 (+2.71%)

06/15/20 Piper Sandler
Shopify upgraded to Overweight from Neutral at Piper Sandler
06/03/20
Zoom Video upgraded to Buy at DA Davidson on 'huge acceleration in growth'
05/21/20 Roth Capital
Roth boosts Shopify target to $750, says valuation remains 'stretched'
05/21/20 Canaccord
Shopify price target raised to $700 from $650 at Canaccord
BYSI BeyondSpring
$16.67 /

+0.11 (+0.66%)

06/09/20 H.C. Wainwright
BeyondSpring data strengthen profile for Plinabulin, says H.C. Wainwright
02/07/20
Fly Intel: Top five analyst initiations
02/07/20 Jefferies
Jefferies starts BeyondSpring at Buy, sees potential for new standard of care
02/07/20 Jefferies
BeyondSpring initiated with a Buy at Jefferies
ISEE Iveric bio
$3.83 /

+0.08 (+2.13%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/08/20 SVB Leerink
Gilead unlikely to be responsive to AstraZeneca's outreach, says SVB Leerink
06/08/20 JPMorgan
JPMorgan's Kasimov gives 'GileastraZeneca' low odds of happening
IRBT iRobot
$75.33 /

+0.765 (+1.03%)

05/26/20
Fly Intel: Top five analyst upgrades
05/26/20 JPMorgan
iRobot upgraded to Neutral on encouraging trends at JPMorgan
05/26/20 JPMorgan
iRobot upgraded to Neutral from Underweight at JPMorgan
05/18/20
Dougherty upgrades iRobot to Buy amid fall in house cleaning services
JKS JinkoSolar
$17.84 /

+0.9 (+5.31%)

04/08/20 GLJ Research
JinkoSolar price target lowered to $6.88 from $7.97 at GLJ Research
03/25/20 Roth Capital
ITC extension 'NOT' in Phase 3 coronavirus rescue package, says Roth Capital
02/11/20 CICC
JinkoSolar upgraded to Outperform from Neutral at CICC
10/07/19 Goldman Sachs
Goldman says U.S. solar makers should benefit from end of bifacial exemption
BP BP
$24.74 /

+0.67 (+2.78%)

06/05/20 UBS
UBS reiterates Buy on BP
06/05/20 UBS
UBS backs Buy on Premier Oil after revised terms for BP assets
06/02/20 Wolfe Research
BP upgraded to Outperform from Peer Perform at Wolfe Research
05/28/20 Societe Generale
BP downgraded to Hold from Buy at Societe Generale
HTZ Hertz
$2.86 /

+0.84 (+41.58%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
CBIO Catalyst Biosciences
$7.44 /

+0.31 (+4.35%)

05/21/20 Raymond James
Catalyst Biosciences initiated with an Outperform at Raymond James
XOG Extraction Oil & Gas
$0.64 /

+0.0601 (+10.36%)

04/23/20 Imperial Capital
Extraction Oil & Gas rating withdrawn at Imperial Capital
04/03/20 Wells Fargo
Wells Fargo says oil markets heading into eye of 'perfect storm' in Q2
03/20/20 Stephens
Stephens upgrades Hess, downgrades 11 others in E&P following oil's melt down
03/20/20 Stephens
Extraction Oil & Gas downgraded to Underweight from Equal Weight at Stephens
XOG Extraction Oil & Gas
$0.64 /

+0.0601 (+10.36%)

SHOP Shopify
$744.50 /

+19.615 (+2.71%)

MRNA Moderna
$62.00 /

+1.84 (+3.06%)

JKS JinkoSolar
$17.84 /

+0.9 (+5.31%)

IRBT iRobot
$75.33 /

+0.765 (+1.03%)

HTZ Hertz
$2.86 /

+0.84 (+41.58%)

CTLT Catalent
$69.58 /

+0.87 (+1.27%)

CBIO Catalyst Biosciences
$7.44 /

+0.31 (+4.35%)

BYSI BeyondSpring
$16.67 /

+0.11 (+0.66%)

BP BP
$24.74 /

+0.67 (+2.78%)

AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

XOG Extraction Oil & Gas
$0.64 /

+0.0601 (+10.36%)

SHOP Shopify
$744.50 /

+19.615 (+2.71%)

MRNA Moderna
$62.00 /

+1.84 (+3.06%)

IRBT iRobot
$75.33 /

+0.765 (+1.03%)

HTZ Hertz
$2.86 /

+0.84 (+41.58%)

CTLT Catalent
$69.58 /

+0.87 (+1.27%)

BP BP
$24.74 /

+0.67 (+2.78%)

AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

XOG Extraction Oil & Gas
$0.64 /

+0.0601 (+10.36%)

SHOP Shopify
$744.50 /

+19.615 (+2.71%)

MRNA Moderna
$62.00 /

+1.84 (+3.06%)

JKS JinkoSolar
$17.84 /

+0.9 (+5.31%)

IRBT iRobot
$75.33 /

+0.765 (+1.03%)

HTZ Hertz
$2.86 /

+0.84 (+41.58%)

CTLT Catalent
$69.58 /

+0.87 (+1.27%)

BP BP
$24.74 /

+0.67 (+2.78%)

AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

SHOP Shopify
$744.50 /

+19.615 (+2.71%)

MRNA Moderna
$62.00 /

+1.84 (+3.06%)

JKS JinkoSolar
$17.84 /

+0.9 (+5.31%)

ISEE Iveric bio
$3.83 /

+0.08 (+2.13%)

IRBT iRobot
$75.33 /

+0.765 (+1.03%)

HTZ Hertz
$2.86 /

+0.84 (+41.58%)

BP BP
$24.74 /

+0.67 (+2.78%)

AZN AstraZeneca
$51.46 /

-0.11 (-0.21%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.